This Antiphospholipid Syndrome Patient Felt Relief When the FDA Approved COVID Boosters
source: pixabay.com

This Antiphospholipid Syndrome Patient Felt Relief When the FDA Approved COVID Boosters

According to a story from Ebene Magazine, the US Food and Drug Administration (FDA) officially authorized that immunocompromised people could receive a third booster shot of the COVID-19 vaccine. This…

Continue Reading This Antiphospholipid Syndrome Patient Felt Relief When the FDA Approved COVID Boosters

Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma

New treatments for unresectable hepatocellular carcinoma (HCC) were approved based on a Phase 3 clinical trial. Richard Kim has recently provided an overview of this study. The Study This study ultimately…

Continue Reading Atezolizumab and Bevacizumab Improves Survival With Unresectable Hepatocellular Carcinoma
Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
biker_becca / Pixabay

Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL

In the Phase 2 LOTIS-2 clinical trial, researchers evaluated the safety, efficacy, and tolerability of Loncastuximab tesirine for patients with aggressive diffuse large B-cell lymphoma (DLBCL). While there are treatment…

Continue Reading Phase 2 Trial Results Show Loncastuximab Tesirine as Beneficial for DLBCL
Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML